单克隆免疫球蛋白沉积病肾移植结局的系统综述
INTRODUCTION: Historical case series of monoclonal Ig deposition disease (MIDD) after kidney transplantation (KTx) reported unfavorable outcomes. Recent case series support more acceptable outcomes in selected patients.…
要点
- 肾移植后 MIDD 复发率较高(54%),中位复发时间 30 个月。
- 移植前达到 VGPR 及以上血液学缓解可显著延长无复发生存。
- 复发后使用克隆导向治疗可延长至移植物失败的时间。
核心结论
- 近期 MIDD 肾移植结局较既往报告更有利,克隆导向治疗可能延长复发后移植物存活。
研究设计与样本
- 对病例系列和病例报告进行个体参与者数据(IPD)的 pooled 分析,检索 MEDLINE、Web of Science、SCOPUS、Cochrane Library 及灰色文献。
主要发现
- 中位随访 46 个月,47 个移植肾(54%)出现复发,中位复发时间 30 个月。
- 达到 VGPR 及以上血液学缓解者估算的中位无复发生存显著更长。
- 5 年和 10 年移植物存活率分别为 67.1% 和 45.9%,复发是多数移植物丢失的主要原因。
- 复发后接受克隆导向治疗者中位至移植物失败时间更长(62 个月 vs 11 个月,P = 0.02)。
- 5 年和 10 年总生存率分别为 83.8% 和 47.4%。
临床怎么用
- 肾移植前应尽可能达到 VGPR 及以上血液学缓解以降低复发风险。
- 移植后需监测 MIDD 复发,复发时考虑克隆导向治疗以延长移植物存活。
局限性
- 基于病例系列和病例报告的 pooled 分析,存在选择偏倚和报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Historical case series of monoclonal Ig deposition disease (MIDD) after kidney transplantation (KTx) reported unfavorable outcomes. Recent case series support more acceptable outcomes in selected patients. METHODS: We performed a pooled analysis of case series and case reports using available individual participant data (IPD). We searched MEDLINE, Web of Science, SCOPUS, Cochrane Library, and gray literature. Recurrence-free survival, graft survival, and overall survival from the time of KTx were analyzed. Sensitivity analyses were performed according to publication type, hematologic response before KTx, exposure to novel agents, and era. RESULTS: Eighty-seven kidney allografts were included from case series and case reports between 1986 and 2023. During the median follow-up of 46 months, recurrence occurred in 47 allografts (54%), at a median of 30 months after KTx. The estimated median recurrence-free survival was significantly longer in patients who achieved a very good partial response (VGPR) hematologic response or better. Graft survival at 5- and 10-years was 67.1% and 45.9% respectively. Recurrence was the main cause of the graft loss in the majority. Among the patients who faced recurrence, the median time from recurrence to graft failure was longer in those who received clone-directed therapies (62 vs. 11 months, P = 0.02). Overall survival rates at 5 and 10 years were 83.8% and 47.4%, respectively. CONCLUSION: More recent outcomes of patients with MIDD after KTx are favorable. Clone-directed therapies in recurrent disease appear to prolong graft survival.
引用
- Heybeli C, Leung N. Systematic Review of Kidney Transplant Outcomes in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2026. PMID: 42011301. doi:10.1016/j.ekir.2026.106372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。